TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.31M | -39.23M | -39.58M | -31.17M | -27.21M |
| Total Depreciation and Amortization | 589.00K | 626.00K | 693.00K | 712.00K | 741.00K |
| Total Amortization of Deferred Charges | 1.11M | 1.05M | 945.00K | 837.00K | 847.00K |
| Total Other Non-Cash Items | 4.86M | 17.47M | 13.64M | 3.72M | -1.38M |
| Change in Net Operating Assets | 765.00K | 2.07M | 3.07M | -2.48M | -7.47M |
| Cash from Operations | -19.99M | -18.01M | -21.24M | -28.37M | -34.48M |
| Capital Expenditure | -305.00K | -918.00K | -927.00K | -880.00K | -1.03M |
| Sale of Property, Plant, and Equipment | 40.00K | 80.00K | 80.00K | 40.00K | 40.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -265.00K | -838.00K | -847.00K | -840.00K | -993.00K |
| Total Debt Issued | 0.00 | 10.00M | 10.00M | 10.00M | 35.00M |
| Total Debt Repaid | -19.00K | -81.00K | -97.00K | -113.00K | -133.00K |
| Issuance of Common Stock | 65.29M | 22.91M | 25.65M | 31.40M | 12.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.81M | -2.07M | -2.07M | -2.07M | -3.11M |
| Cash from Financing | 63.46M | 30.76M | 33.48M | 39.22M | 44.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.20M | 11.91M | 11.40M | 10.01M | 9.03M |